Navigation Links
Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinson's Disease on Their Largest Commercial Plan
Date:8/19/2013

BURLINGTON, Mass., Aug. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that up to 60 percent of surveyed U.S. managed care organization (MCO) pharmacy and medical directors expect to reimburse several late-stage emerging Parkinson's disease (PD) therapies on their largest risk-based commercial plan. Profiled in the report are four emerging agents that target primarily underserved populations, including IPX-066 (Impax Laboratories' Rytary), an extended-release reformulation of levodopa (multiple brands, generics), the mainstay of PD treatment, Acadia Pharmaceuticals' pimavanserin for PD-related psychotic symptoms, Novartis's mavoglurant (AFQ-056) for dyskinesias and Newron Pharmaceuticals/Zambon Pharma/Meiji Seika Pharma's MAO-B inhibitor safinamide.

The U.S. Physician and Payer Forum report entitled The Complex Parkinson's Disease Treatment Algorithm: U.S. Physician and Payer Perspectives on the Current and Future Landscape finds that formulary exclusion can be common for current PD brands, with at least one-third of MCO respondents indicating that their largest commercial plans and Medicare prescription drug plans exclude or block key brands from coverage. The most recent market entrant, UCB's dopamine agonist Neupro (rotigotine), is similarly covered, despite offering once-daily dosing and unique transdermal delivery. Nevertheless, when reimbursing key current brands, surveyed payers largely include such agents on tiers 2 and 3 (i.e. commonly preferred and non-preferred brands, respectively), and generally expect similar tier placement for the emerging agents profiled if priced at approximately $10 per day or higher.

The report also finds that surveyed neurologists estimate the eligible patient pool for emerging products queried to be no less than one quarter of their diagnosed PD patients, on average. Moreover, they anticipate that up to two-thirds of eligible patients would be treated with each product within one year of launch, with IPX-066 projected to capture the greatest patient share at approximately 25 percent of diagnosed PD patients if reimbursed on a preferred tier.

"Cost and reimbursement factors have a prominent role in determining the uptake of a PD therapy, but clinical considerations most influence prescribing decisions," said Decision Resources Senior Business Insights Analyst Nadja Rozovsky, Ph.D. "Despite the potential for certain constraints on reimbursement and finite patient eligibility, commercial opportunity remains for key late-stage investigational products in light of lingering unmet need."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Health-Conscious Women are Sixty Percent More Likely to Prefer Popular Brand-Name Drugs, Even if They Cost More
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
4. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
5. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
6. "AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
7. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
8. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
9. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
10. Elekta Technology at Work in 100 Percent of Americas Top Cancer Hospitals
11. New Analysis Shows Illicit Drug Use May Vary by Payer Type: Detection Rates as High as 17 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016   Health ... advancement of new health technologies, announced today " 10 ... achievements in health tech over the past ten years.   ... For nearly a decade, Health 2.0 has served as ... showcased and connected with thousands of technologies, companies, innovators, ...
(Date:2/11/2016)... Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... amniotic membrane and other birth tissues, human skin and ... and market advanced products and therapies, announced today that ... Global Healthcare Conference in New York ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology:
(Date:2/12/2016)... York, NY (PRWEB) , ... February 12, 2016 ... ... edition of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing ... Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. ... and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans ... categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors ...
(Date:2/12/2016)... ... ... US Sport Camps is pleased to announce the addition of junior golf ... the host site and directing the camps is PGA Professional and 2008 Iowa State ... recent years around Des Moines and are fortunate to have such a well-respected instructor ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Healthcare careers ... the five most searched jobs via the website of healthcare staffing leader Aureus Medical ... travel nurse jobs , travel therapy positions and in travel and ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... growth in the field of long term care. With that, says Patrick Loughney, ... healthcare professionals in administrative roles in long term care environments. His company, which ...
Breaking Medicine News(10 mins):